Meeting on the Mesa · Briefing Room

Sign in to continue

Use your Made Scientific account — the same login you use for the Made platform.

Rep review · Made OS Share links show the prospect-safe view only.
Internal — not for distribution · Made Scientific commercial intelligence
Made OS · Field intelligence

Meeting on the Mesa · Briefing Room

Field intelligence & shareable collateral for the Made team.

This page

Rep Intel sheet

Everything we’ve gathered on each attending account: science, trials, funding, news, CRM, and the outreach we’ve drafted. For your prep, not for the prospect.

Safe to send

Shareable prospect page

A warm, prospect-safe one-pager you can send to anyone excited to meet at the Mesa. Copy its link below and share it.

Shareable prospect link Send this to the prospect.
Selected account

Orca Bio

Tier 1 · Priority Customer
Allogeneic T-cell therapy · hematologic malignancies Owner: Karen Wu US-West Meeting on the Mesa
5
Clinical trials
1
Funding filings
0
News hits
0
Grants
2
Contacts
1
Speakers
01Executive summary

Orca Bio is a Tier 1 customer (US-West, Karen Wu) developing allogeneic T-cell therapies for hematologic malignancies, with Orca-T in Phase 3 and Orca-Q in Phase 1. With 3 won opps and no open opportunities, the relationship is mature but needs strategic re-engagement. The clearest opportunity is scaling commercial-readiness capacity for Orca-T ahead of a BLA, plus tech-transfer for Orca-Q.

02Who’s attending / speaking
CG
Corinne Glock
Head of US Field Market Access
NF
Nate Fernhoff, Ph.D.Speaker · Panel
Panelist
SessionLeadership Perspectives: Beyond the Breakthrough

Deep intelligence

End-to-end enrichment · status: enriched
03L3 science readout
Modality: allogeneic T cell
Aligns with Made’s core cell-therapy processing; subset engineering demands robust analytical development and lot-to-lot consistency.
Clinical stage: Phase 3
Commercial scale-up within 12–24 months; center the talk on commercial readiness, validation, CMC.
04Development / trials
Discovery
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
Furthest stage
Commercial
ProgramPhaseRegistry status
Precision-T (Orca-T)
Phase 1
ACTIVE_NOT_RECRUITING
Orca-Q Phase 1
Phase 1
RECRUITING
Orca-T RIC/NMA
Phase 2
RECRUITING
Orca-T EAP
—
AVAILABLE
05Signal readout

Five active/recruiting trials including a Phase 3 pivotal and an EAP indicate aggressive clinical momentum. One SEC filing and zero news imply a capital-efficient, heads-down posture — an optimal window for a strategic manufacturing partnership before competitive CDMOs crowd in post-data.

06Funding filings
FormFiledFiler
Form D 2020-07-09 Orca BioSystems Inc.
07CRM facts
CRM statusCustomer
OwnerKaren Wu (rep)
TerritoryUS-West (sfdc)
Open opps0
Won opps3
Intel statusEnriched
08Generated outreach
Portal 2 drafted · Email 0 · LinkedIn 0
Corinne Glock rep: Karen Wu Manufacturing → exit positioning

Hi Corinne, With Orca-T advancing through Phase 3, your manufacturing strategy is now a board-level question… I’ll be at Meeting on the Mesa, would be great to connect. Best, Karen

Nate Fernhoff rep: Karen Wu Platform scale-up

Hi Nate, … Best, Karen

09Talk track

How to approach them at the Mesa

Karen should reconnect with Corinne Glock on launch geography/supply strategy, then use Nate Fernhoff’s panel to explore Orca-Q peer-to-peer. With no open opps despite Phase 3, the angle is consultative: as Orca-T nears readout and BLA prep, discuss commercial-scale allogeneic capability + CMC.

10Rep notes

Rep notes

Working notes on this account — typed or dictated. Saved to Made OS, internal only.

Internal tool
Author
Ready
Karen Wu Sep 3, 2026 typed

Met Corinne briefly last ISCT — warm. Focus the Mesa chat on commercial supply, not price.